Frontlight ResearchEarly access
CompletedNo phase
Effect of Thrombolysis on 30-day Mortality in Intermediate High Risk Pulmonary Patients With Low Bleeding Risk
Key facts
- Who runs it
- Ain Shams University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 100 people enrolled
- Started
- 1 Jul 2023
- Ended
- 1 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Thrombolytic therapy for the study group in the form of streptokinase or recombinant tissue plasminogen activator
- Unfractionated Heparin IV
- Record updated
- 29 January 2026
Who can take part
- Age
- 25 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Patients with intermediate high risk pulmonary embolism diagnosed according to clinical probability using revised Geneva Score and diagnosis confirmed by echocardiography and Troponin I or T level and CT pulmonary angiography
Who cannot take part
- Ischaemic stroke in previous 6 months
- Major trauma, surgery, or head injury in previous 3 weeks
- Transient ischaemic attack in previous 6 months
- o High risk PE; Intermediate low risk PE; low risk PE; Patients with left ventricular systolic dysfunction (ischemic or non-ischemic etiology); Patients with chronic lung diseases (obstructive or restrictive); Patients with contraindications to thrombolysis:
- History of haemorrhagic stroke or stroke of unknown origin
- Active bleeding
- Severe hypertension (systolic BP >180 mmHg)
- Advanced liver disease
- Active Peptic ulcer
- Patients who develop hypotension or bradycardia or allergic reaction requiring discontinuation of Streptokinase infusion
- Patients with HAS-BLED score greater than or equals 3 (high bleeding risk for thrombolysis)
- Bleeding diathesis (known inherited bleeding disorder, for example, haemophilia, platelet count <50,000/uL)
- Central nervous system neoplasm
- Oral anticoagulation
- Pregnancy or first post-partum week
- Non-compressible puncture sites
- Traumatic resuscitation
- Infective endocarditis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of investigators was to study the effect and safety of Thrombolysis in Intermediate high risk pulmonary embolism patients with low bleeding risk as regards Mortality and bleeding events.
The 2 groups in the trial
- Control groupExisting treatment, for comparison
This arm will receive standard anticoagulation in the form of intravenous unfractionated heparin
Treatment: Unfractionated Heparin IV
- Study groupExisting treatment, for comparison
This arm will receive thrombolytic therapy in the form of either streptokinase or recombinant tissue plasminogen activator
Treatment: Thrombolytic therapy for the study group in the form of streptokinase or recombinant tissue plasminogen activator
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 29 January 2026